State of the heart in the metabolic syndrome

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 15, Issue 4, 2005, Pages 239-241

  De Simone, Giovanni ^a  

^a FEDERICO II UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 23944514393     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2005.06.006     Document Type: Editorial

References (24)

1. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
2. Grundy SM, Hansen B, Smith Jr SC, Cleeman JI, Kahn RA. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004;109:551-6.
3. Grundy SM, Cleeman JI, Merz CN, Brewer Jr HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39.
4. Ferrannini E, Natali A, Capaldo B, Lehtovirta M, Jacob S, Yki-Jarvinen H. Insulin resistance, hyperinsulinemia, and blood pressure: role of age and obesity European Group for the Study of Insulin Resistance (EGIR). Hypertension 1997;30:1144-9.
5. WHO. Definition of metabolic syndrome in definition, diagnosis and classification of diabetes and its complications. Report of a WHO consultation. Part 1: Diagnosis and classification of diabetes mellitus. WHO/NCD/NCS/99.2. 1999. Geneve, World Health Organization - Department of Noncommunicable Disease Surveillance.
6. Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003;9:237-52.
7. Alberti G. IDF consensus on the metabolic syndrome: definition and treatment, 〈http://www.cmeondiabetes.com/pub/idf.consensus.on.the. metabolic.syndrome.definition.and.treatment.php〉; 4-13-2005. 1st International Congress on "Prediabetes" and the Metabolic Syndrome, Epidemiology, Management and Prevention of Diabetes and Cardiovascular Disease.
8. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003;52:1210-4.
9. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-16.
10. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004;110:1251-7.
11. de Simone G, Devereux RB, Palmieri V, Roman MJ, Celentano A, Welty TK, et al. Relation of insulin resistance to markers of preclinical cardiovascular disease: the Strong Heart Study. Nutr Metab Cardiovasc Dis 2003;13:140-7.
12. Westerbacka J, Vehkavaara S, Bergholm R, Wilkinson I, Cockcroft J, Yki-Jarvinen H. Marked resistance of the ability of insulin to decrease arterial stiffness characterizes human obesity. Diabetes 1999;48:821-7.
13. Yki-Jarvinen H, Westerbacka J. Vascular actions of insulin in obesity. Int J Obes Relat Metab Disord 2000;24(Suppl. 2):S25-8.
14. Devereux RB, Alderman MH. Role of preclinical cardiovascular disease in the evolution from risk factor exposure to development of morbid events. Circulation 1993;88:1444-55.
15. de Simone G, Palmieri V, Bella JN, Celentano A, Hong Y, Oberman A, et al. Association of left ventricular hypertrophy with metabolic risk factors: the HyperGEN study. J Hypertens 2002;20:323-31.
16. Chinali M, Devereux RB, Howard BV, Roman MJ, Bella JN, Liu JE, et al. Comparison of cardiac structure and function in American Indians with and without the metabolic syndrome (the Strong Heart Study). Am J Cardiol 2004;93:40-4.
17. Schillaci G, Pirro M, Vaudo G, Gemelli F, Marchesi S, Porcellati C, et al. Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol 2004;43:1817-22.
18. Drazner MH, Dries DL, Peshock RM, Cooper RS, Klassen C, Kazi F, et al. Left ventricular hypertrophy is more prevalent in blacks than whites in the general population: The Dallas Heart Study. Hypertension 2005;46:124-9.
19. de Simone G. African-Americans and Caucasians: different genes or different exposure? Hypertension 2005;46:23-4.
20. Celentano A, Crivaro M, Roman MJ, Pietropaolo I, Greco R, Pauciullo P, et al. Left ventricular geometry and arterial function in hypercholesterolemia. Nutr Metab Cardiovasc Dis 2001;11:312-9.
21. de Simone G, Devereux RB, Kizer JR, Chinali M, Bella JN, Oberman A, et al. Body composition and fat distribution influence systemic hemodynamics in the absence of obesity: the HyperGEN Study. Am J Clin Nutr 2005;81(4):757-61.
22. Esposito K, Giugliano D. The metabolic syndrome and inflammation: association or causation? Nutr Metab Cardiovasc Dis 2004;14(5):228-32.
23. Bo M, Raspo S, Morra F, Isaia G, Cassader M, Fabris F, et al. Body fat and C-reactive protein levels in healthy non-obese men. Nutr Metab Cardiovasc Dis 2004;14(2):66-72.
24. Reilly MP, Wolfe ML, Rhodes T, Girman C, Mehta N, Rader DJ. Measures of insulin resistance add incremental value to the clinical diagnosis of metabolic syndrome in association with coronary atherosclerosis. Circulation 2004;110(7):803-9.